Systemic administration of resveratrol suppress the nociceptive neuronal activity of spinal trigeminal nucleus caudalis in rats  by Takehana, Shiori et al.
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Although  a  modulatory  role  has  been  reported  for the  red  wine  polyphenol  resveratrol  on several  types
of ion channels  and excitatory  synaptic  transmission  in the nervous  system,  the  acute  effects  of  resvera-
trol  in  vivo,  particularly  on  nociceptive  transmission  of  the  trigeminal  system,  remain  to be  determined.
The  aim  of  the  present  study  was  to investigate  whether  acute  intravenous  resveratrol  administration  to
rats  attenuates  the  excitability  of wide  dynamic  range  (WDR)  spinal  trigeminal  nucleus  caudalis  (SpVc)
neurons  in  response  to  nociceptive  and non-nociceptive  mechanical  stimulation  in  vivo.  Extracellular
single  unit  recordings  were  made  from  18  SpVc  neurons  in response  to  orofacial  mechanical  stimula-
tion  of pentobarbital-anesthetized  rats.  Responses  to both  non-noxious  and noxious  mechanical  stimuli
were  analyzed  in the  present  study.  The  mean  ﬁring  frequency  of SpVc  WDR  neurons  in response  to
both  non-noxious  and  noxious  mechanical  stimuli  was  inhibited  by resveratrol  (0.5–2  mg/kg,  i.v.)  and
maximum  inhibition  of the discharge  frequency  of both  non-noxious  and  noxious  mechanical  stimuli
was  seen  within  10 min.  These  inhibitory  effects  were  reversed  after  approximately  20  min.  The rela-lternative medicine tive  magnitude  of  inhibition  by  resveratrol  of SpVc  WDR  neuronal  discharge  frequency  was  signiﬁcantly
greater  for  noxious  than  non-noxious  stimulation.  These  results  suggest  that,  in  the absence  of  inﬂam-
matory  or  neuropathic  pain,  acute  intravenous  resveratrol  administration  suppresses  trigeminal  sensory
transmission,  including  nociception,  and  so resveratrol  may  be used  as  a complementary  and  alternative
medicine  therapeutic  agent  for the  treatment  of  trigeminal  nociceptive  pain,  including  hyperalgesia.
© 2015  The  Authors.  Published  by Elsevier  Inc. This  is an  open  access  article  under  the CC  BY-NC-ND. Introduction
Resveratrol (trans-3,4′,5-trihydroxystilbene), is plant polyphe-
ol that is found in red wine and various food products (Fremont,
000; Pervaiz, 2003). Resveratrol has several beneﬁcial biological
ctions, including anti-oxidative, anti-inﬂammatory, neuroprotec-
ive, anticancer, and cardioprotective effects (Leiro et al., 2005;
ermudez-Ocasna et al., 2006; Perez-Severiano et al., 2008; Pervaiz,
Abbreviations: SpVc, trigeminal spinal nucleus caudalis; WDR, wide dynamic
ange; CAM, complementary and alternative medicine; TRP, transient receptor
otential; TRPA1, TRP ankyrin 1; DRG, dorsal root ganglion; ANOVA, analysis of
ariance; PAG, periaqueductal gray; 5-HT3 receptor, 5-hydroxytrypytamine type 3
eceptor.
∗ Corresponding author. Fax: +81 42 769 2212.
E-mail address: m-takeda@azabu-u.ac.jp (M.  Takeda).
ttp://dx.doi.org/10.1016/j.brainresbull.2015.11.011
361-9230/© 2015 The Authors. Published by Elsevier Inc. This is an open access article 
/).license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
2003). Recent reports have described the use of complementary
and alternative medicines (CAM), such as herbal medicines and
acupuncture, for the treatment of persistent clinical chronic pain
(Rao et al., 1999; Konvicka et al., 2008; Rosenberg et al., 2008),
and the potential effects of diet and dietary supplementation on
conditions associated with pain have been the focus of consider-
able research (Shir et al., 2001; Ernest, 2003; Tall and Raja, 2004).
Because resveratrol has no known toxic side effects (Russo, 2007),
it could be a candidate CAM for the therapeutic treatment of pain.
Recent reports suggest that resveratrol modulates the neuronal
excitability of the peripheral and central nervous systems via tran-
sient receptor potential (TRP) channels and voltage-dependent ion
channels (Grannados-Soto et al., 2002; Kim et al., 2005; Liew et al.,
2005; Gao and Hu, 2005; Yu et al., 2013). For example, TRP ankyrin
1 (TRPA1) modulates mechanotransduction in primary sensory
neurons (Kwan et al., 2009), and it has been demonstrated that
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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esveratrol is a potent inhibitor of TRPA1 in vitro and in vivo (Yu
t al., 2013), suggesting that resveratrol attenuates the genera-
or potential via the mechanical transduction process. In addition,
esveratrol modulates the sodium and potassium currents in dorsal
oot ganglion (DRG) neurons that are associated with the genera-
ion of action potentials (Kim et al., 2005; Grannados-Soto et al.,
002). Conversely, in the hippocampal slice preparation, resver-
trol signiﬁcantly suppressed the glutamate-induced currents in
ost-synaptic CA1 pyramidal neurons (Gao et al., 2006) that con-
ribute to excitatory synaptic transmission. In fact, there are reports
hat resveratrol decreases action potential duration and L-type Ca2+
urrents in excitable tissues (Liew et al., 2005). Together, these ﬁnd-
ngs strongly suggest that systemic resveratrol administration may
uppress sensory transmission, including nociception, in the both
eripheral and central nervous systems.
The spinal trigeminal nucleus is an important relay station in
he transmission of orofacial sensory information and this nucleus
s functionally subdivided into three nuclei (from rostral to caudal):
ralis, interpolarlis and caudalis (Sessle, 2000). It is well known
hat, in addition to the upper cervical (C1–C2) dorsal horn, the
pinal trigeminal nucleus caudalis (SpVc) is an important relay
tation for trigeminal nociceptive inputs from inﬂammation and
issue injury (Takeda et al., 2012). Chronic pathological condi-
ions, such as tissue inﬂammation can, change the properties of
omatic sensory pathways, leading to hyperalgesia and allodynia
Scholz and Woolf, 2002). Changes in the excitability of primary
fferent neurons (peripheral sensitization) alter information pro-
essing in the spinal trigeminal nucleus or higher centers (Millan,
999). Previous studies have demonstrated that wide dynamic
ange (WDR) neurons in the SpVc region have an important role in
he mechanism underlying hyperalgesia/allodaynia and/or referred
ain associated with orofacial pain (Takeda et al., 2000, 2005,
012; Nishikawa et al., 2004). In addition, intravenous adminis-
ration of lidocaine, a sodium channel blocker, has been shown
o attenuate the trigeminal nociceptive reﬂex and nociceptive
timulation-induced C1 WDR  neuronal excitability, possibly via an
nhibitory synaptic mechanism, which may  contribute to trigem-
nal referred pain (Takeda et al., 2009). On the basis of these
bservations, we hypothesized that intravenous resveratrol admin-
stration would attenuate noxious stimulation-induced excitability
f SpVc neuronal activity through a central mechanism, as is the
ase for local anesthetic agents and/or analgesic drugs. However,
he acute effects of resveratrol on trigeminal neuronal activity
n vivo in response to nociceptive and non-nociceptive mechanical
timulation remain to be determined.
Thus, the aim of the present study was to investigate whether
cute intravenous administration of resveratrol to rats could atten-
ate the excitability of nociceptive WDR  SpVc neuronal activity
n vivo in response to mechanical stimulation.
. Materials and methods
The experiments described herein were approved by the Animal
se and Care Committee of Azabu University and were performed
n accordance with the guidelines of the International Association
or the Study of Pain (Zimmermann, 1983). Every effort was made
o minimize the number of animals used and their suffering.
.1. Extracellular single unit recording of WDR  neuronal activity
n the SpVcElectrophysiological recordings were made in 18 adult male
istar rats weighing 250–290 g. Rats were anesthetized with pen-
obarbital sodium (45 mg/kg, i.p.) and anesthesia was  maintained
ith additional doses of 2–3 mg/kg per hour pentobarbital sodiumulletin 120 (2016) 117–122
through a cannula into the jugular vein, as required. The level of
anesthesia was conﬁrmed by the absence of the corneal reﬂex
and a lack of response to paw pinching. Rectal temperature was
maintained at 37.0 ± 0.5 ◦C with a homeothermic blanket during
recording. Rats were placed in a stereotaxic apparatus, and the
activity of a single neuron from the SpVC region was  recorded
extracellularly. Single neuron activity was  recorded using a glass
micropipette ﬁlled with 2% Pontamine sky blue and 0.5 M sodium
acetate according to the stereotaxic coordinates of Paxinos and
Watson (1986). Neuronal activity was ampliﬁed (DAM 80; World
Precision Instruments), ﬁltered (0.3–10 kHz), monitored with an
oscilloscope (SS-7672; Iwatsu, Tokyo, Japan), and recorded on a
polygraph (NEC-Sanei 8M14) for subsequent off-line analysis using
PowerLab and Chart 5 software (ADInstruments, Oxford, UK).
2.2. Experimental protocols
Extracellular recordings of SpVc WDR  unit activity were made as
follows. Mechanical stimulation was  used as a stimulus to identify
the receptitive ﬁeld quickly and to avoid sensitization of periph-
eral receptors. Single units that responded to stimulation of the
left side of the orofacial facial skin (whisker pad) with a brush
and a set of von Frey hairs (Semmes-Weinstein Monoﬁlaments;
North Coast Medical, Gilroy, CA, USA) were identiﬁed. Noxious
pinch stimulation, which evoked a pain sensation when applied
to a human subject, was  applied to the orofacial area using for-
ceps. After identiﬁcation of WDR  SpVc neurons responding to
stimulation of the whisker pad, we determined whether there
was spontaneous discharge. The threshold for mechanical stimu-
lation was  determined using non-noxious and noxious mechanical
stimulation (5 s) with Von Frey hairs (1, 2, 4, 6, 10, 15, 26, 60 g)
at the interval of 5 s. The mechanical receptive ﬁeld of neurons
was mapped by probing the facial skin with Von Frey hairs, and
then outlined on a life-sized drawing of a rat on tracing paper.
The WDR  neuronal discharges induced by mechanical stimulation
were quantiﬁed by subtracting background activity from evoked
activity. Spontaneous discharge frequencies were determined over
a period of 2–5 min. If no discharge was recorded, the cell was
deemed a silent neuron. The mean ﬁring rate of SpVc WDR  neurons
evoked by mechanical stimulation was compared before and after
drug administration. Since previous studies have demonstrated
that wide dynamic range (WDR) neurons in the SpVc region have
an important role in the mechanism underlying hyperalgesia and
referred pain associated with orofacial pain (Takeda et al., 2000,
2005, 2012; Nishikawa et al., 2004), the focus of the present study
was on the effects of resveratrol on SpVc WDR  neuronal activity,
but we  did not examine nociceptive-speciﬁc neurons (Ness and
Randich 2006). Post-stimulus histograms (bin = 100 ms)  were gen-
erated in response to each stimulus. The effects of resveratrol (0.5,
1, and 2 mg/kg, i.v.; equivalent to 1, 5, and 10 mM,  respectively),
injected through a cannula into the jugular vein, were evaluated
5, 10, 20, and 30 min  after administration because peak effect and
recovery were thought to occur during this period. Concerning the
dose-dependent experiment, six rats were used in the each dose
(0.5, 1.0 and 2 mg/kg, i.v.) of resveratrol, respectively. Resveratrol
was dissolved in dimethyl sulfoxide (DMSO). The stock solution was
stored at −20◦C in small aliquots until use and diluted in saline.
The mean spontaneous and mechanical stimulation-induced dis-
charges rates, as well as the mechanical threshold before and after
intravenous administration of resveratrol, were evaluated in the
present study.2.3. Identiﬁcation of recording sites
Recording sites of SpVc WDR  neuronal activity were identiﬁed
as described previously (Takeda et al., 2000, 2012). Brieﬂy, at the
S. Takehana et al. / Brain Research Bulletin 120 (2016) 117–122 119
Fig. 1. Effect of intravenous injection of resveratrol on SpVc WDR  neuronal activity evoked by non-noxious, noxious, and mechanical stimulation. (A) Receptive ﬁeld of the
whisker  pad in the facial skin. Blackened area (high threshold) and hatched area (low threshold) indicate the location and size of the receptive ﬁelds. (B) Distribution of SpVc
WDR  neurons responding to non-noxious and noxious mechanical stimulation of the facial skin (n = 18). The number below the each drawing indicates the frontal plane
in  relation to the obex. (C) Typical example of SpVc WDR  neuronal activity evoked by non-noxious (1–10 g) and noxious mechanical stimulation (15 g, 26 g, 60 g, noxious
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cinch)  of the orofacial skin. Upper trace: SpVc WDR  neuronal activity; lower trace:
y  mechanical stimulation. (D) Typical examples of SpVc WDR  neuronal activity ev
echanical stimulation: before and 5 and 20 min  after administration of 2 mg/kg res
nd of the recording sessions, rats were deeply anesthetized and
nodal DC currents (30 A, 5 min) were passed through a record-
ng micropipette. The rats were then perfused transcardially with
aline and 10% formalin. Frozen coronal sections (30 m)  were cut
nd stained with hematoxylin–eosin. Recording sites were identi-
ed from the blue spots, and the path of the electrode tracks was
onstructed in combination with micromanipulator readings.stimulus histogram. Inset: example of the waveform of an action potential evoked
by non-noxious (1–10 g), noxious (15–60 g) mechanical stimuli and noxious pinch
rol. Effects of intravenous administration of vehicle on SpVc WDR  neuronal activity.
2.4. Data analysis
Values are expressed as the mean ± SEM. Statistical analyses
were performed using two-way repeated-measures analysis of
variance (ANOVA) followed by Tukey–Kramer or Dunnett’s post hoc
tests for electrophysiological data. P < 0.05 was  considered signiﬁ-
cant.
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Fig. 2. Time course of intravenous resveratrol administration on the mean ﬁring
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Fig. 3. Dose-dependent suppression by resveratrol of the mean ﬁring frequency ofrequency of SpVc WDR  neurons responding to non-noxious, noxious, and nox-
ous pinch mechanical stimulation. #P < 0.05 compared with 6-g stimulus; *P < 0.05
ompared with before resveratrol administration, n = 6.
. Results
.1. General properties of SpVc WDR  neurons innervating facial
kin
Extracellular single unit activity was recorded from 18 neurons
n the SpVc. The SpVc neurons responding to non-noxious and nox-
ous mechanical stimulation exhibited a somatic receptive ﬁeld in
he orofacial area (mainly whisker pad; Fig. 1A), as described pre-
iously (Takeda et al., 2000, 2012). In addition, all these neurons
esponded to mechanical stimulation of the receptive ﬁeld inner-
ated by ophthalmic and maxillary branches. Two of the 18 units
xhibited spontaneous discharges. As shown in Fig. 1B, recording
ites were found in Layers I–III (n = 10; 56%) and IV–V (n = 8; 44%)
n the SpVc (obex—0.5 ∼ −2 mm).  Typical examples of SpVc WDR
euronal unit responses are shown in Fig. 1C. Graded mechanical
timulation was applied to the most sensitive area of the recep-
ive ﬁeld, which exhibited increased ﬁring frequency of SpVc WDR
eurons in proportion to stimulus intensity. The mean mechanical
timulation-induced spike threshold was 2.8 ± 1.3 g (n = 18). Every
euron recorded belonged to the WDR  category of neurons (Takeda
t al., 2012).
.2. Effects of resveratrol on excitability of SpVc WDR  neurons in
esponse to non-noxious stimuli
A typical example of the effect of resveratrol (2 mg/kg, i.v.)
n the excitability of SpVc WDR  neurons in response to non-
oxious mechanical stimulation is shown in Fig. 1D. Five minutes
fter injection of resveratrol, non-noxious (1–10 g) mechanical
timulation-evoked SpVc WDR  neuronal activity was inhibited, but
his inhibition disappeared, with activity returning to control lev-
ls, within approximately 20 min. There were no obvious changes
n the size of the receptive ﬁeld (before vs after, 19.1 ± 0.2 mm2 vs
8.5 ± 0.1 mm2, NS) or in the mechanical threshold after resver-
trol administration. SpVc WDR  neuronal activity evoked by
on-noxious mechanical stimulation is summarized in Fig. 2. After
esveratrol injection, there was a signiﬁcant decrease in the mean
ring rate of non-noxious mechanical stimulation-evoked SpVc
DR neuronal activity, which eventually returned to control lev-
ls. Mean ﬁring rates before and after resveratrol were 4.9 ± 1.7
s. 2.3 ± 1.0 Hz, respectively, in response to the 6-g stimulus and
0.2 ± 2.5 vs. 5.6 ± 2.9 Hz, respectively, in response to the 10-gSpVc WDR  neurons responding to noxious, and noxious pinch mechanical stimula-
tion. *P < 0.05 compared with 0.5 mg/kg, i.v., resveratrol, n = 6.
stimulus (n = 6, P < 0.05 for both). As indicated in Fig. 3, the inhibi-
tion by resveratrol of non-noxious mechanical stimulation-evoked
SpVc WDR  neuronal activity had a tendency for dose-dependent,
but not signiﬁcant.
3.3. Effects of resveratrol on excitability of SpVc WDR  neurons in
response to noxious stimuli
Fig. 1 also shows typical examples of the effects of resvera-
trol (2 mg/kg, i.v.) on the excitability of SpVc WDR  neurons in
response to noxious mechanical and noxious pinch stimulation.
Noxious (15–60 g) mechanical stimulation-evoked SpVc WDR  neu-
ronal activity was  inhibited 5–10 min  after injection of resveratrol,
but this inhibition disappeared, with activity returning to con-
trol levels in approximately 20 min. Similarly, SpVc WDR  neuronal
activity in response to noxious pinch stimulation was inhibited
5 min  after injection of resveratrol, with responses returning to
control levels within 20 min.
As indicated in Fig. 2, the mean ﬁring rates of SpVc WDR  neurons
evoked by noxious mechanical and pinch stimulation decreased
signiﬁcantly after injection of resveratrol compared with control
(before drug injection): 7.7 ± 2.9 vs. 17.5 ± 2.9 Hz, respectively, for
the 15-g stimulus; 22.5 ± 4.8 vs. 40.1 ± 4.3 Hz, respectively, for
the 60-g stimulus; and 30.9 ± 8.1 vs 52.2 ± 7.2 Hz, respectively, for
the pinch stimulus (n-6, P < 0.05 for all). The suppression of SpVc
WDR  neuronal ﬁring in response to noxious mechanical and pinch
stimulation was signiﬁcantly greater following intravenous injec-
tion of 0.5 versus 2 mg/kg resveratrol (28.1 ± 12.2% vs. 62.5 ± 2.1%,
respectively, for the 15-g stimulus; 27.3 ± 5.8% vs. 65.0 ± 8.3%,
respectively, for the 60-g stimulus; and 34.8 ± 6.9% vs. 80.9 ± 15.1%,
respectively, for the pinch stimulus (n = 6, P < 0.05 for all; Fig. 3). No
signiﬁcant change was observed in the mean receptive ﬁeld size
after resveratrol administration (before vs after 16.9 ± 0.3 mm2 vs
14.5 ± 0.1 mm2, NS). There were no changes in the spontaneous
ﬁring rate after resveratrol administration. Intravenous adminis-
tration of vehicle had no signiﬁcant effect on either spontaneous or
evoked (non-noxious, noxious mechanical, and pinch stimulation)
activity of SpVc WDR  neurons (n = 2; Fig. 2D).
3.4. SpVc WDR  neuronal activity in response to noxious vs.
non-noxious stimuli after resveratrolFinally, we compared the relative inhibitory effect of 2 mg/kg,
i.v., resveratrol on responses to non-noxious and noxious stim-
uli. The mean magnitude of inhibition by resveratrol of SpVc WDR
neuronal discharge frequency was signiﬁcantly greater for noxious
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han non-noxious stimuli (62.9 ± 2.3% vs. 32.7 ± 6.8%, respectively;
 = 6, P < 0.05).
. Discussion
The present study provides evidence that, in the absence of
nﬂammatory or neuropathic pain, acute intravenous resveratrol
uppresses trigeminal sensory transmission, including nociception.
herefore, resveratrol may  be considered a potential CAM agent for
he treatment of trigeminal nociceptive pain without side effects.
.1. Intravenous resveratrol suppresses excitability of SpVc WDR
eurons
The primary ﬁndings of the present study are as follows:
i) mean SpVc WDR  neuronal ﬁring rate in response to both
on-noxious and noxious mechanical stimuli was inhibited by
esveratrol (0.5–2 mg/kg, i.v.); (ii) the inhibition of the discharge
requency in response to both non-noxious and noxious mechan-
cal stimuli was reversible and occurred within approximately
0 min; and (iii) injection of vehicle had no signiﬁcant effect on
pVc WDR  neuronal activity in response to either non-noxious
r noxious mechanical or pinch stimuli. In a previous study, the
ntinociceptive effect of resveratrol against the nociceptive reﬂex
as observed with a dose as low as 2 mg/kg, i.p. (10 mM),  with no
urther increases in effect observed with higher doses (Gentilli et al.,
001). In the present study, following the systemic administration
f 10 mM resveratrol, the drug entered the general circulation and
as diluted in the bloodstream to a calculated concentration of
pproximately 100 M,  and this concentration still had a signiﬁ-
ant effect on the nociceptive transmission of the SpVc. It has been
hown that 100 M resveratrol signiﬁcantly inhibits glutaminergic
xcitatory synaptic transmission in hippocampal slices (Gao et al.,
006). Together, these ﬁndings suggest that under in vivo con-
itions, acute intravenous resveratrol administration suppresses
rigeminal nociceptive transmission in the SpVc, at the level of
econdary neurons.
.2. Suppression of SpVc WDR  neuron excitability by resveratrol
.2.1. Peripheral mechanisms
The mechanism of nociceptive sensory signaling depends on
he following four general processes: (i) transduction from periph-
ral terminals that transduce external stimuli; (ii) generation of
ction potentials; (iii) propagation of action potentials along axons;
nd (iv) transmission to central terminals, which form the presy-
aptic elements of the ﬁrst synapses in the sensory pathways in
he central nervous system (for reviews, see Harriot and Gold
009; Takeda et al., 2011). With regard to the effect of resvera-
rol on excitable tissue in the nervous system, previous reports
uggest that resveratrol modulates the excitability of neurons in
he peripheral nervous system via activation of voltage-dependent
nd TRP channels (Grannados-Soto et al., 2002; Kim et al., 2005;
iew et al., 2005; Gao and Hu, 2005; Yu et al., 2013). Recently,
eng et al. (2015) reported that, in vitro, mechanical stimuli induce
echanosensitive currents via mechanosensitive channels such
s TRPA1 to trigger mechanotransduction in trigeminal neurons
nnervating the inner walls of the anterior eye chamber. In addi-
ion, TRPA1 has been reported to modulate mechanotransduction
n primary sensory neurons (Kwan et al., 2009) and resveratrol
as been shown to be a potent inhibitor of TRPA1 in vitro and
n vivo (Yu et al., 2013), suggesting that resveratrol attenuates
he generator potential and inhibits action potential ﬁring via
he mechanical transduction process. Moreover, resveratrol mod-
lates the sodium and potassium currents in DRG neurons that
re associated with the generation of action potentials (Kim et al.,ulletin 120 (2016) 117–122 121
2005; Grannados-Soto et al., 2002). Kim et al. (2005) demonstrated
that resveratrol predominantly inhibits Na+ currents in acutely
dissociated DRG neurons, indicating that resveratrol inhibits the
generation of action potentials. On the basis of these results, it can
be speculated that resveratrol inhibits the excitability of peripheral
terminals of the trigeminal nerve by modulating both the trans-
duction (generator potential) and generation (initiation of action
potentials) processes. However, further studies are needed to elu-
cidate the precise mechanisms of action of resveratrol.
4.2.2. Central mechanisms
Gao et al. (2006) reported that in hippocampal slices resveratrol
signiﬁcantly suppressed glutamate-induced currents in post-
synaptic CA1 pyramidal neurons without having any presynaptic
effects. In addition, Gao et al. (2006) indicated that N-methyl-d-
aspartate (NMDA) receptors were more sensitive to resveratrol
than -amino-3-hydroxy-5-methyl-4-isoxazole proprionic acid
(AMPA) receptors. There are also reports that resveratrol decreases
action potential duration and L-type Ca2+ currents in ventricular
myocytes (Liew et al., 2005; Zhang et al., 2006). Thus, it is possible
that resveratrol suppresses the glutaminergic excitatory synaptic
transmission of SpVc by inhibiting post-synaptic glutamate recep-
tors and presynaptic Ca2+ channels.
Alternatively, a previous study indicated that systemic resver-
atrol exhibits dose-dependent antinociceptive effects via an
opioidergic mechanism, because pretreatment of rats with nalox-
one, an opioid antagonist, completely blocked the analgesic effect
of resveratrol (Gupta et al., 2004). Opiates acting via the -opioid
receptor partially inhibit evoked inhibitory GABAergic pre- and
post-synaptic potentials in the periaquadutal gray (PAG; Chieng
and Christie, 1994). Blockade of -opioid receptors increases
neuronal activity in the PAG via GABAergic disinhibition, which
can then activate serotonergic (5-hydroxytrypytamine [5-HT])
neurons in the nucleus raphe magnus (the PAG–nucleus raphe
magnus–trigeminal pathway; Gebahrts and Randich, 1990; Takeda
et al., 2002). In addition, resveratrol facilitates 5-HT3 receptor-
mediated ion currents (Lee et al., 2011). Previous studies have
reported that nociceptive stimulation-evoked SpVc/C1 neuron
activity is suppressed by conditioning peripheral nerve stimulation
via 5-HT3 receptor-mediated GABAergic inhibition (Tanimoto et al.,
2004; Oshima et al., 2005). Collectively, these observations suggest
that resveratrol suppresses excitatory synaptic transmission of the
SpVc via activation of 5-HT3 receptor-mediated GABAergic inhibi-
tion and/or via activation of endogenous opioidergic mechanisms.
However, further studies are needed to clarify these possibilities.
4.3. Functional signiﬁcance of resveratrol suppression of
nociceptive stimulation-induced excitability of SpVc neurons
In a previous study we  found that intravenous administration
of lidocaine, a sodium channel blocker, attenuated the trigeminal
nociceptive reﬂex and nociceptive stimulation-induced C1 WDR
neuronal excitability possibly via inhibitory synaptic mechanisms
acting through strychnine-sensitive glycine receptors, which may
contribute to trigeminal referred pain (Takeda et al., 2009). This
evidence suggests that resveratrol can attenuate central trigemi-
nal nociceptive pain transmission. In the present study, we  found
that resveratrol decreases the mechanical stimulation-induced dis-
charge frequency of SpVc neurons after both non-noxious and
noxious stimuli, but that nociceptive input to SpVc WDR  neurons is
more sensitive to resveratrol than non-nociceptive input. Although
the precise reason why there is a difference in resveratrol sensitivity
between nociceptive and non-nociceptive inputs remains unclear,
it can be postulated that resveratrol predominantly inhibits central
mechanisms through both excitatory synaptic transmission in the
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Yu, L., Wang, S., Kogure, Y., Yamamoto, S., Noguchi, K., Dai, Y., 2013. Modulation of
TRP  channels by resveratrol and other stilbenoids. Mol. Pain 9, 3.
Zimmermann, M.,  1983. Ethical guidelines for investigations of experimental pain22 S. Takehana et al. / Brain Rese
pVc and descending inhibitory (including endogenous opioider-
ic) mechanisms.
Finally, CAM, including herbal medicines and acupuncture, have
een used to treat persistent clinical chronic pain (Rao et al., 1999;
onvicka et al., 2008; Rosenberg et al., 2008). In addition, studies
ave investigated the potential effects of diet and dietary supple-
entation on conditions associated with pain (Shir et al., 2001;
rnest, 2003; Tall and Raja, 2004). Interestingly, resveratrol has
o known toxic side effects (Russo, 2007), so the possibility exists
hat resveratrol may  be a candidate CAM, speciﬁcally a therapeutic
nalgesic agent. Because incisions associated with surgery cause
cute pain and surgery has been identiﬁed as a potential major
ause of chronic pain (Perkins and Kehlet, 2000; Kehlet et al.,
006), it is possible that resveratrol could effectively reduce clinical
ain, including postoperative pain (Locher-Claus et al., 2005; Tillu
t al., 2012). The results of the present study indicate that acute
ntravenous resveratrol administration suppresses trigeminal noci-
eptive transmission without inﬂammatory or neuropathic pain.
s such, resveratrol may  be a potential therapeutic agent for the
reatment of trigeminal nociceptive pain, including clinical pain.
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